ArticleActa oncologica (Stockholm, Sweden)2026
Survival and relapse of Danish patients with thymic epithelial tumors.
Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThis study aims to evaluate survival, relapse, comorbidities, and prognostic factors in patients with thymic epithelial tumours (TETs) to improve risk stratification for TET-related mortality and relapse and support evidence-based follow-up and treatment strategies. Patient/material and methods: The cohort consists of consecutive Danish patients diagnosed with thymoma, thymic carcinoma (TC), or thymic neuroendocrine tumor (NET) between January 1st, 2015 and December 31st, 2020, with follow-up data available. Data were collected from online medical records including disease characteristics, survival outcomes, comorbidities, and relapse. Statistical analyses were performed in R 4.3.2 and the prognostic value baseline traits were analyzed using Cox Proportional Hazards models.
resultsOur cohort comprised 282 patients with a mean diagnostic age of 65 years and the following histological distribution: thymoma (85%), TC (13.6%), and NET (1.4%). During the 72-month mean follow-up, 65 deaths occurred yielding overall survival (OS) of 81% in patients with thymoma and 47% in patients with TC. TET-related deaths predominated in TC, yielding a cancer-specific survival) of 53% compared with 96% in thymoma. Reduced OS was associated with increasing age (p < 0.001) and advanced Tumor, Node, Metastasis-stage (III p < 0.05; IV p < 0.001). Disease progression was verified in 13/201 (6%) of thymoma patients with R0 or R1 resection.
interpretationWe report a high OS of Danish TET patients compared to existing population-based studies. The occurrence of TET-related mortality and disease progression in patients with thymoma and TC, highlights the need for long-term follow-up and therefore risk stratification in TET management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.